GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (FRA:EX9) » Definitions » Cyclically Adjusted PB Ratio

Exelixis (FRA:EX9) Cyclically Adjusted PB Ratio : 5.88 (As of May. 02, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Exelixis Cyclically Adjusted PB Ratio?

As of today (2024-05-02), Exelixis's current share price is €21.93. Exelixis's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €3.73. Exelixis's Cyclically Adjusted PB Ratio for today is 5.88.

The historical rank and industry rank for Exelixis's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:EX9' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 5.1   Med: 14.24   Max: 223
Current: 5.36

During the past years, Exelixis's highest Cyclically Adjusted PB Ratio was 223.00. The lowest was 5.10. And the median was 14.24.

FRA:EX9's Cyclically Adjusted PB Ratio is ranked worse than
80.43% of 644 companies
in the Biotechnology industry
Industry Median: 1.74 vs FRA:EX9: 5.36

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Exelixis's adjusted book value per share data for the three months ended in Mar. 2024 was €6.636. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €3.73 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Exelixis Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Exelixis's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exelixis Cyclically Adjusted PB Ratio Chart

Exelixis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.91 12.47 7.59 5.08 6.12

Exelixis Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.77 5.37 5.81 6.12 5.80

Competitive Comparison of Exelixis's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Exelixis's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exelixis's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exelixis's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Exelixis's Cyclically Adjusted PB Ratio falls into.



Exelixis Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Exelixis's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=21.93/3.73
=5.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exelixis's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Exelixis's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=6.636/129.4194*129.4194
=6.636

Current CPI (Mar. 2024) = 129.4194.

Exelixis Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.012 100.560 0.015
201409 -0.233 100.428 -0.300
201412 -0.475 99.070 -0.621
201503 -0.692 99.621 -0.899
201506 -0.854 100.684 -1.098
201509 -0.292 100.392 -0.376
201512 -0.567 99.792 -0.735
201603 -0.612 100.470 -0.788
201606 -0.720 101.688 -0.916
201609 0.100 101.861 0.127
201612 0.292 101.863 0.371
201703 0.383 102.862 0.482
201706 0.450 103.349 0.564
201709 0.677 104.136 0.841
201712 0.813 104.011 1.012
201803 1.831 105.290 2.251
201806 2.227 106.317 2.711
201809 2.626 106.507 3.191
201812 3.774 105.998 4.608
201903 4.065 107.251 4.905
201906 4.351 108.070 5.211
201909 4.794 108.329 5.727
201912 4.978 108.420 5.942
202003 5.172 108.902 6.146
202006 5.271 108.767 6.272
202009 5.082 109.815 5.989
202012 4.957 109.897 5.838
202103 5.125 111.754 5.935
202106 5.386 114.631 6.081
202109 5.677 115.734 6.348
202112 6.136 117.630 6.751
202203 6.503 121.301 6.938
202206 7.030 125.017 7.278
202209 7.802 125.227 8.063
202212 7.251 125.222 7.494
202303 7.343 127.348 7.462
202306 7.286 128.729 7.325
202309 7.074 129.860 7.050
202312 6.856 129.419 6.856
202403 6.636 129.419 6.636

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Exelixis  (FRA:EX9) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Exelixis Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Exelixis's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Exelixis (FRA:EX9) Business Description

Industry
Traded in Other Exchanges
Address
1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Exelixis (FRA:EX9) Headlines

No Headlines